Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials.
The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.
It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Ian Smith |
Contact Details
Address: 45 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781 430 8200 |
| Website | stoketherapeutics.com |
Stock Details
| Ticker Symbol | STOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001623526 |
| CUSIP Number | 86150R107 |
| ISIN Number | US86150R1077 |
| Employer ID | 47-1144582 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian F. Smith A.C.A., C.P.A. | Interim Chief Executive Officer and Director |
| Dr. Arthur O. Tzianabos Ph.D. | Interim Executive Chairman |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder and Independent Director |
| Thomas Edward Leggett | Chief Financial Officer |
| Dr. Edward M. Kaye M.D., Ph.D. | Advisor and Director |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer |
| Isabel Aznarez Ph.D. | Co-Founder, Head of Research and Senior Vice President |
| Doug Snow | Director of Communications and Investor Relations |
| Jonathan Allan J.D. | Corporate Secretary and General Counsel |
| Dawn Kalmar | Chief Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | 144 | Filing |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | SCHEDULE 13G/A | Filing |
| Apr 15, 2025 | SCHEDULE 13G | Filing |
| Mar 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |